CDK2/4 dual inhibitor (Iambic Therapeutics)

N/A

Report date: 2024/06/17 16:33:51
NMEFirst In Class

Base Information

Drug NameCDK2/4 dual inhibitor (Iambic Therapeutics)
Drug Alias NameIAM-C1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 2 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 2Cyclin-dependent kinase 4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIambic Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIambic Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A